Coeliac screening: benefits and barriers

Despite being one of the most common life-long health conditions in Europe, many people with coeliac disease remain undiagnosed. However, evidence shows that lengthy diagnostic delays do have a negative effect on quality of life and can reduce life-expectancy. The condition is estimated to affect 1% of the European population. It is genetically-determined and causes inflammation to the small intestine, leading to diarrhoea, weight loss and fatigue. Women with coeliac disease can also suffer from repeated, early miscarriages. 

A recent report from Ludvigsson et al,¹ published in the UEG Journal, looks at the benefits and barriers to screening for coeliac disease using serologic testing methods in high-risk groups as well as in the general population. The report concluded that screening of first-degree relatives of people with coeliac disease, people with type 1 diabetes, irondeficiency anaemia, Down’s syndrome and other high-risk groups may be appropriate.

“This latest research highlights the value of serologic testing for coeliac disease, particularly for those patients with symptoms that might be due to the condition and in all asymptomatic individuals from high-risk groups,” said Professor Antonio Gasbarrini, director Internal Medicine and Gastroenterology Division at Gemelli University Hospital in Rome, Italy. “It is vital that we start to take positive action across Europe to tackle this prevalent condition and reduce its serious health consequences.”